FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Federal Register

Regulatory Review Period for Barhemsys

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Acacia Pharmas Barhemsys (amisulpride), indicat...

Federal Register

Guide on Unique Device Identifier Info

Federal Register notice: FDA posts a final guidance entitled Unique Device Identification System: Form and Content of the Unique Device Identifier.

Federal Register

Regulatory Review Period for Zephyr Valve Implant

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Pulmonx Corp.s Zephyr Endobronchial Valve Impla...

Human Drugs

Porter Wants OIG Probe of Company Influence on FDA

Rep. Katie Porter calls for an HHS inspector general probe of drug company influence on FDA drug evaluations and approvals.

Human Drugs

Athenex Evaluating New Cancer Drug Trial

Responding to a complete response letter, Athenex says it is working on a new clinical trial of oral paclitaxel and encequidar to treat metastatic bre...

Medical Devices

Hyalex Ortho Breakthrough Status for Cartilage Repair

FDA grants Hyalex Orthopedics a breakthrough device designation for the Hyalex Cartilage System, intended for use in repairing cartilage defects.

Human Drugs

FDA Identifies Need for Better Addressing Drug Shortages

FDA says drug shortages remain a significant problem and it has identified two issues that need ongoing work to help address the situation.

Human Drugs

Appealing a CRL in Court May be Worth It: Attorneys

Two Hyman, Phelps & McNamara attorneys say a recent case indicated there may be circumstances in which it is worth challenging in court FDAs position ...

Human Drugs

Mercks Keytruda Gets Expanded Label

FDA approves an expanded label for Mercks Keytruda (pembrolizumab) as monotherapy for treating certain patients with locally advanced cutaneous squamo...

Human Drugs

FDA Mostly Denies Celgene/Abraxis Abraxane Petition

FDA denies all but one request in a Celgene/Abraxis 2015 petition involving Abraxane.